Ipeleng Kgosiemang-Xaba | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Ipeleng Kgosiemang-Xaba
University of the Free State, South Africa
Ipeleng Kgosiemang-Xaba
Affiliation University of the Free State
Country South Africa
Scopus ID 56707418000
Documents 9
Citations 241
h-index 7
Subject Area Oncology
Event Health Scientists Awards

Ipeleng Kgosiemang-Xaba is presented in this academic recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions.[1]

Abstract

Ipeleng Kgosiemang-Xaba is presented in this recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions. The profile therefore highlights an interdisciplinary trajectory centered on biologically active South African plants, cancer-related mechanisms, and translational opportunities while maintaining a neutral distinction between documented scientific outputs and award recognition.[3]

Keywords

Euphorbia species; cancer; medicinal plants; pharmacological properties; toxicity; secondary metabolites; breast cancer; antiproliferative activity; iron oxide nanoparticles; iron dioxide nanoparticles; natural-product pharmacology; phytochemicals. These terms are aligned particularly with the publication literature addressing Southern African Euphorbia species and experimental anticancer research.[2]

Introduction

Ipeleng Kgosiemang-Xaba’s research profile reflects an interdisciplinary interest in oncology, medicinal plants, pharmacology, and biomedical technology. Her publications address Euphorbia-derived bioactive compounds and experimental anticancer approaches, including nanoparticle systems evaluated against breast cancer cell lines. These themes place natural-product research within a framework of cancer research and translational biomedical investigation.[1]

Research Profile

Ipeleng Kgosiemang-Xaba has published work spanning molecular biology, medicinal plants, phytochemistry, pharmacology, and oncology. Her research includes studies of Euphorbia species and their secondary metabolites, together with experimental investigations of antiproliferative effects and nanoparticle-mediated approaches. The available literature indicates a continuing interest in linking biological resources with therapeutic research questions.[2][3]

Research Contributions

Ipeleng Kgosiemang-Xaba’s contributions include systematic examination of Southern African Euphorbia species, their medicinal uses, toxicity, phytochemical constituents, and reported pharmacological activities. Her research also includes green synthesis of iron-based nanoparticles using Euphorbia tirucalli and evaluation of antiproliferative activity against breast cancer cell lines, thereby connecting plant science with experimental oncology.[2][3]

Publications

Ipeleng Kgosiemang-Xaba is associated with publications addressing Euphorbia pharmacology, anticancer research, nanoparticle synthesis, and molecular biology. A 2025 review in Plants examined medicinal uses, toxicity, secondary metabolites, and pharmacological properties of Southern African Euphorbia species, while a 2023 Journal of Experimental Nanoscience article evaluated iron-based nanoparticles and breast cancer models.[5]

Research Impact

Ipeleng Kgosiemang-Xaba’s research impact can be considered through the relevance of her publications to natural-product pharmacology, cancer biology, and biomedical nanotechnology. Her work contributes evidence on underexplored Southern African plant resources and experimental anticancer strategies. Citation activity and publication visibility provide measurable indicators, while broader clinical significance requires further validation.[3]

Award Suitability

Ipeleng Kgosiemang-Xaba’s documented research themes are compatible with an Innovative Research Award focused on oncology, natural-product discovery, and biomedical technology. Her publications demonstrate research activity involving anticancer constituents, Euphorbia species, phytochemicals, and nanoparticle systems. Award suitability should remain subject to the event’s published formal criteria, independent verification, and comparative assessment.[4]

Conclusion

Ipeleng Kgosiemang-Xaba presents a research profile connecting Southern African medicinal plants with pharmacology, nanotechnology, and oncology. Her publications provide evidence of work on Euphorbia chemistry, toxicity, antiproliferative activity, and cancer-oriented experimental systems. Collectively, these outputs support recognition of an emerging interdisciplinary research direction without implying clinical efficacy beyond published evidence.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Ipeleng Kgosiemang-Xaba, Author ID 56707418000. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56707418000
  2. Kgosiemang, I. K. R., Lefojane, R., Adegoke, A. M., Ogunyemi, O., Mashele, S. S., & Sekhoacha, M. P. (2025). Pharmacological significance, medicinal use, and toxicity of extracted and isolated compounds from Euphorbia species found in Southern Africa: A review. Plants, 14(3), 469.https://doi.org/10.3390/plants14030469
  3. Kgosiemang, I. K. R., Adegoke, A. M., Mashele, S. S., & Sekhoacha, M. P. (2023). Green synthesis of iron oxide and iron dioxide nanoparticles using Euphorbia tirucalli: Characterization and antiproliferative evaluation against three breast cancer cell lines. Journal of Experimental Nanoscience, 18(1), 2276276.https://doi.org/10.1080/17458080.2023.2276276
  4. Parvez, M., Qhanya, L. B., Mthakathi, N. T., Kgosiemang, I. K. R., et al. (2016). Molecular evolutionary dynamics of cytochrome P450 monooxygenases across kingdoms: Special focus on mycobacterial P450s. Scientific Reports, 6, 33099.https://doi.org/10.1038/srep33099
  5. Kgosiemang, I. K. R. (2024). Targeted delivery of iron, cobalt and magnesium nanoparticles incorporating anticancer constituents of Euphorbia species for treatment of breast cancer. Doctor of Health Sciences in Biomedical Technology, Central University of Technology, Free State.https://cutscholar.cut.ac.za/items/e527142e-a8dc-4c94-8eb1-121facf1eff7/full

Aimaz Afrough | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Aimaz Afrough
UT Southwestern Medical Center, United States

Aimaz Afrough
Affiliation UT Southwestern Medical Center
Country United States
Scopus ID 43660943000
Documents 63
Citations 1,171
h-index 19
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0003-2645-8557

Aimaz Afrough is a researcher affiliated with UT Southwestern Medical Center whose scholarly work primarily focuses on oncology, molecular cancer biology, translational medicine, and clinically relevant cancer investigations. The research portfolio reflects sustained contributions to understanding tumor biology, improving diagnostic approaches, and supporting evidence-based therapeutic development. Publications indexed in major scientific databases demonstrate active participation in multidisciplinary cancer research while promoting scientific collaboration and clinical translation within contemporary oncology research.[1]

Abstract

Aimaz Afrough investigates oncology through multidisciplinary research integrating molecular biology, translational medicine, cancer diagnostics, and therapeutic innovation. Published studies emphasize clinically meaningful discoveries that improve understanding of tumor development, disease progression, biomarker identification, and treatment response. The research demonstrates collaboration across biomedical disciplines while supporting evidence-based clinical practice and precision oncology. Scientific publications indexed in recognized databases contribute to advancing cancer research, strengthening translational applications, encouraging interdisciplinary collaboration, and providing valuable knowledge that informs future investigations, patient-centered healthcare strategies, and sustainable improvements in oncology outcomes worldwide.[2]

Keywords

Oncology, Cancer Biology, Tumor Microenvironment, Precision Oncology, Molecular Oncology, Cancer Biomarkers, Translational Medicine, Immuno-Oncology, Clinical Oncology, Cancer Therapeutics

Introduction

Aimaz Afrough contributes to oncology research by investigating biological mechanisms underlying cancer and translating laboratory discoveries into clinically meaningful knowledge. Research activities strengthen interdisciplinary collaboration while supporting innovative diagnostic methods, precision medicine, and therapeutic development that improve understanding of complex malignancies across diverse healthcare environments.[3]

Research Profile

Aimaz Afrough maintains an academic profile centered on oncology, emphasizing molecular mechanisms, translational investigations, biomarker discovery, and collaborative biomedical research. Publications demonstrate commitment to scientific rigor while addressing clinically relevant questions that support evidence generation and continuous advancement of modern cancer research and healthcare innovation.[1]

Research Contributions

Aimaz Afrough has contributed to collaborative investigations exploring cancer biology, translational oncology, molecular diagnostics, and therapeutic strategies. Research findings enhance scientific understanding of disease mechanisms while supporting precision medicine initiatives, improving clinical interpretation, and encouraging continued innovation across multidisciplinary oncology research communities worldwide.[4]

Publications

Aimaz Afrough has authored and coauthored peer-reviewed publications indexed within recognized scientific databases. Published studies address oncology, molecular medicine, and translational research while reflecting sustained scholarly engagement, interdisciplinary collaboration, methodological quality, and contributions supporting scientific communication, clinical relevance, and future biomedical investigation.[2]

Research Impact

Aimaz Afrough demonstrates measurable research impact through scholarly publications, scientific collaborations, and dissemination within oncology. The research supports evidence-based medicine, encourages knowledge exchange, informs future investigations, and contributes valuable insights that strengthen translational cancer research and broader biomedical scientific advancement internationally.[1]

Award Suitability

Aimaz Afrough demonstrates qualifications appropriate for consideration within the Innovative Research Award through consistent oncology research, interdisciplinary collaboration, scholarly publications, and contributions supporting translational medicine. Scientific activities reflect innovation, academic integrity, and continuing commitment to advancing biomedical knowledge through evidence-based cancer research.[5]

Conclusion

Aimaz Afrough continues contributing to oncology through collaborative scientific research emphasizing translational relevance, molecular discoveries, and clinical applicability. Continued scholarly activities strengthen biomedical knowledge, encourage innovation, support evidence-based healthcare, and provide meaningful foundations for future advances within international oncology research communities.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Aimaz Afrough, Author ID 43660943000. Scopus.
    https://www.scopus.com/pages/authors/43660943000
  2. ORCID. (n.d.). Aimaz Afrough ORCID Record.
    https://orcid.org/0000-0003-2645-8557
  3. Google Scholar. (n.d.). Scholar Profile: Aimaz Afrough.
    https://scholar.google.com/citations?user=2ENlGnkAAAAJ&hl=en&oi=ao
  4. ResearchGate. (n.d.). Aimaz Afrough Research Profile.
    https://www.researchgate.net/profile/Aimaz-Afrough
  5. Health Scientists Awards. (n.d.). Innovative Research Award.
    https://healthscientists.org/

Bina Kashyap | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Bina Kashyap
Agartala Government Dental College, India

Bina Kashyap
Affiliation Agartala Government Dental College
Country India
Scopus ID 39561184400
Documents 28
Citations
389
h-index
11
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0001-9192-8645

Bina Kashyap is an academic researcher affiliated with Agartala Government Dental College, India. Her scholarly work contributes to oncology-related oral health research, emphasizing clinical dentistry, oral pathology, cancer prevention, and evidence-based healthcare. Through peer-reviewed scientific publications, she has participated in advancing understanding of oral diseases associated with malignancy and related diagnostic approaches. Her research activities demonstrate continued engagement with interdisciplinary healthcare investigations and provide meaningful contributions to dental oncology literature.[1]

Abstract

Bina Kashyap has developed an academic profile centered on oncology-related oral healthcare, integrating clinical dentistry with evidence-based scientific investigation. Her published studies contribute to understanding oral manifestations associated with cancer, diagnostic evaluation, pathology, preventive strategies, and multidisciplinary patient management. Through collaboration with healthcare professionals and academic researchers, her work supports improved clinical decision-making and encourages continual advancement in dental oncology research. The consistency of her scholarly contributions, institutional affiliation, and participation in peer-reviewed scientific communication collectively demonstrate sustained professional engagement within oncology and oral health sciences, reflecting recognized standards of academic research excellence.[1][2]

Keywords

Oral Oncology, Oral Cancer, Oral Pathology, Dental Oncology, Precancerous Lesions, Oral Medicine, Clinical Dentistry, Histopathology, Cancer Diagnosis, Public Health Dentistry.

Introduction

Bina Kashyap contributes to oncology research through dental science by examining oral diseases, pathological conditions, diagnostic practices, and preventive healthcare. Her academic publications strengthen interdisciplinary collaboration between dentistry and medicine while supporting evidence-based clinical management and improved patient outcomes across oral healthcare settings.[2]

Research Profile

Bina Kashyap maintains an active scholarly profile through peer-reviewed publications indexed in international databases. Her affiliation with Agartala Government Dental College reflects continuing involvement in academic research, clinical education, and collaborative scientific activities related to oncology, oral pathology, and dental healthcare advancement.[1]

Research Contributions

Bina Kashyap has contributed to scientific understanding by investigating oral pathological conditions, cancer-related lesions, diagnostic approaches, and preventive dental practices. Her collaborative research encourages evidence-based treatment planning while supporting broader awareness regarding early detection and multidisciplinary management within oral oncology research.[3]

Publications

Bina Kashyap has authored and co-authored peer-reviewed publications addressing oral oncology, oral pathology, dental diagnostics, and associated healthcare topics. Her scholarly articles appear within recognized academic journals, contributing validated scientific evidence that supports clinical practice, education, and future interdisciplinary research developments.[2]

Research Impact

Bina Kashyap demonstrates measurable academic influence through internationally indexed publications that support evidence-based dentistry and oncology research. Her scientific output contributes valuable knowledge for clinicians, educators, and researchers while promoting continuous improvement in diagnostic accuracy, patient care, and interdisciplinary healthcare collaboration.[1]

Award Suitability

Bina Kashyap demonstrates qualifications consistent with recognition through the Innovative Research Award by maintaining scholarly productivity, contributing oncology-related dental research, encouraging collaborative scientific inquiry, and supporting clinical advancement. Her academic record reflects commitment to research quality, professional integrity, and healthcare innovation.[4]

Conclusion

Bina Kashyap represents a dedicated academic researcher whose work integrates dentistry with oncology through scientifically validated investigation. Her publications, institutional engagement, and commitment to evidence-based healthcare collectively support continued professional recognition while encouraging future advancements in oral cancer research and clinical practice.[1]

External Links

References

  1. Elsevier. (n.d.). Scopus author details: Bina Kashyap, Author ID 39561184400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=39561184400
  2. ORCID. (n.d.). Bina Kashyap – ORCID Research Profile.
    https://orcid.org/0000-0001-9192-8645
  3. Soiniemi, L., Kanniainen, M., Suomela, E., Ramsay, S., Jäsberg, H., Kashyap, B., & Kullaa, A. M. (n.d.). Transmembrane mucin 1 is a polarity protein in the organization of apical surface microplicae in oral epithelium. https://pubmed.ncbi.nlm.nih.gov/41146464/
  4. Ramsay, S., Hyvärinen, E., Mikkonen, J., González-Arriagada, W. A., Salo, T., Lopes, M. A., Kashyap, B., & Kullaa, A. M. (n.d.). Salivary metabolite-based prediction of radiotherapy-induced oral mucositis and candidiasis. https://pubmed.ncbi.nlm.nih.gov/41372697/
  5. Kashyap, B., Naumanen, K., Mikkonen, J., Dekker, H., Schulten, E., Bloemena, E., Pasonen-Seppänen, S., & Kullaa, A. (n.d.). Irradiation alters the expression of MUC1, CD44 and hyaluronan in oral mucosal epithelium. https://doi.org/10.3390/biomedicines10112816

Khadijeh Dizaji Asl | Oncology | Editorial Board Member

Published on by Health Scientists

Editorial Board Member

Khadijeh Dizaji Asl
Islamic Azad University, Iran

                        Khadijeh Dizaji Asl
Affiliation Islamic Azad University
Country Iran
Scopus ID 57221391321
Documents 21
Citations 207
h-index 8
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0003-0920-9583

Khadijeh Dizaji Asl is an oncology-focused researcher affiliated with Islamic Azad University, Iran. Her scholarly activities contribute to the advancement of cancer-related research, clinical understanding, and evidence-based scientific inquiry. Through publications indexed in major academic databases and an established citation record, she has demonstrated sustained engagement with oncology research and interdisciplinary scientific collaboration.[1][2]

Abstract

Khadijeh Dizaji Asl is an oncology researcher affiliated with Islamic Azad University whose scholarly record reflects active participation in cancer-related investigations and biomedical research. Her publications address topics associated with oncology, disease mechanisms, clinical outcomes, and evidence-based healthcare approaches. Indexed academic outputs, citation performance, and an established h-index indicate measurable scientific visibility within her research field. Through collaboration, publication, and dissemination of findings, she contributes to the broader understanding of oncological challenges and supports the development of knowledge that informs future research directions and clinical applications in cancer science.[1][2]

Keywords

Oncology, Cancer Research, Clinical Oncology, Biomedical Science, Tumor Biology, Medical Research, Health Sciences, Evidence-Based Medicine, Cancer Studies, Scientific Publications

Introduction

Khadijeh Dizaji Asl has developed a research profile centered on oncology and related biomedical disciplines. Her scholarly work contributes to the growing body of scientific literature addressing cancer mechanisms, treatment perspectives, and healthcare outcomes. Academic indexing and citation metrics demonstrate continued engagement with internationally visible research activities.[1]

Research Profile

Affiliated with Islamic Azad University, Khadijeh Dizaji Asl has authored publications indexed in Scopus and other academic platforms. Her research interests primarily involve oncology-related investigations, scientific collaboration, and dissemination of evidence supporting advancements in cancer research and healthcare knowledge.[1][2]

Research Contributions

Her scholarly contributions include participation in studies that enhance understanding of oncological processes and clinical implications. Through peer-reviewed publications, she has supported scientific discussion surrounding cancer research, contributing data and analyses that strengthen evidence-based approaches within the field.[1][3]

Publications

The publication portfolio of Khadijeh Dizaji Asl includes twenty-one indexed documents with measurable citation performance. Her research outputs appear within recognized scholarly channels and contribute to the dissemination of oncology-focused findings relevant to researchers, clinicians, and healthcare stakeholders.[1]

Research Impact

With more than two hundred citations and an h-index of eight, her work demonstrates scholarly recognition within the scientific community. These indicators suggest that published findings have informed subsequent studies and contributed to ongoing academic discourse in oncology research.[1][2]

Award Suitability

Based on her documented research productivity, citation record, and commitment to oncology scholarship, Khadijeh Dizaji Asl demonstrates qualifications aligned with recognition programs that value scientific contribution, academic engagement, and advancement of health-related research within the international research community.[4]

Conclusion

Khadijeh Dizaji Asl has established a visible academic presence through oncology-focused research, indexed publications, and scholarly citations. Her contributions support scientific understanding of cancer-related topics and reflect ongoing participation in research activities that advance evidence-based knowledge and healthcare scholarship.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Khadijeh Dizaji Asl, Author ID 57221391321. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221391321
  2. ORCID. (n.d.). Khadijeh Dizaji Asl: ORCID record 0000-0003-0920-9583.https://orcid.org/0000-0003-0920-9583
  3. Google Scholar. (n.d.). Scholar profile of Khadijeh Dizaji Asl.https://scholar.google.com/citations?user=fyQaW6YAAAAJ&hl=en&oi=ao
  4. ResearchGate. (n.d.). Khadijeh Dizaji Asl researcher profile.https://www.researchgate.net/profile/Khadijeh-Dizaji-Asl

Dimitrios Bouklas | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Dimitrios Bouklas
General Hospital of Athens “G. Gennimatas”
          Dimitrios Bouklas
Affiliation General Hospital of Athens “G. Gennimatas”
Country Greece
Scopus ID 57372362800
Documents 5
Citations 2
h-index 1
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0002-5858-0357

Dimitrios Bouklas is affiliated with the General Hospital of Athens “G. Gennimatas” in Greece and contributes to oncology-related clinical and scientific investigations. His scholarly profile demonstrates engagement in cancer research and healthcare studies, supported by indexed publications and citation records available through international academic databases.[1][2]

Abstract

Dimitrios Bouklas has developed a research profile focused on oncology and clinical healthcare studies within a hospital-based environment. His published work contributes to understanding cancer-related conditions, patient management approaches, and evidence-based medical practice. Indexed publications demonstrate participation in multidisciplinary scientific investigations and collaboration with healthcare professionals. Through dissemination of peer-reviewed research, his work supports ongoing efforts to improve clinical knowledge and patient outcomes. The available scholarly metrics, including indexed documents, citations, and author identifiers, indicate active engagement in scientific communication and contribution to contemporary oncology literature and healthcare research initiatives.[1][2]

Keywords

Oncology, Cancer Research, Clinical Oncology, Healthcare Research, Medical Science, Hospital-Based Research, Cancer Care, Clinical Studies, Patient Outcomes, Scientific Publications

Introduction

The advancement of oncology relies on continuous clinical investigation and evidence-based practice. Dimitrios Bouklas contributes to this field through participation in research activities associated with cancer care, clinical assessment, and healthcare improvement, supporting scientific understanding and the translation of research findings into medical practice.[1]

Research Profile

His academic profile is represented through indexed publications in oncology and related healthcare disciplines. Affiliated with a major healthcare institution in Greece, he participates in scientific studies addressing clinical challenges, patient care considerations, and disease-related investigations within contemporary medical research environments.[1][2]

Research Contributions

Dimitrios Bouklas has contributed to peer-reviewed investigations involving oncology-focused clinical research. His work supports scientific discussion on disease management, healthcare outcomes, and multidisciplinary medical collaboration. These contributions enhance the evidence base available to clinicians and researchers working in cancer-related healthcare settings.[1]

Publications

The researcher’s publication record includes indexed scientific articles documented within Scopus and other scholarly platforms. These works reflect involvement in oncology and clinical medicine research, contributing to the dissemination of healthcare knowledge through peer-reviewed academic literature and professional scientific communication.[1][3]

Research Impact

Research impact is reflected through citation activity, indexed publications, and professional visibility across scholarly databases. Although at an early citation stage, the documented work contributes to oncology literature and supports ongoing academic engagement within clinical and healthcare research communities.[1][4]

Award Suitability

Dimitrios Bouklas demonstrates qualifications aligned with the objectives of the Innovative Research Award through documented scholarly activity, oncology-focused investigations, and participation in scientific publication. His commitment to advancing clinical knowledge and supporting evidence-based healthcare makes him a relevant candidate for academic recognition.[1][2]

Conclusion

The academic profile of Dimitrios Bouklas reflects meaningful engagement in oncology research and scientific communication. Through publications, institutional affiliation, and participation in healthcare studies, he contributes to the advancement of medical knowledge and demonstrates characteristics consistent with emerging research excellence.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Dimitrios Bouklas, Author ID 57372362800. Scopus.

    https://www.scopus.com/authid/detail.uri?authorId=57372362800

  2. ORCID. (n.d.). Dimitrios Bouklas – ORCID Record.

    https://orcid.org/0000-0002-5858-0357

  3. ResearchGate. (n.d.). Dimitrios Bouklas Research Profile and Publications.

    https://www.researchgate.net/profile/Dimitrios-Bouklas

  4. Google Scholar. (n.d.). Dimitrios Bouklas Citation Profile.

    https://scholar.google.com/citations?user=h6mhYUIAAAAJ&hl=en&oi=ao

Rasha Elsabagh | Oncology | Research Excellence Award

Published on by Health Scientists

Dr. Rasha Elsabagh | Oncology | Research Excellence Award

Researcher | Animal Health Research Institute(AHRI) | Egypt

Rasha H. Elsabagh is a multidisciplinary immunology specialist and cancer stem cell researcher with extensive expertise spanning stem cell biology, immuno-oncology, translational cancer research, and veterinary biomedical sciences. She currently serves as a researcher at the Animal Health Research Institute, where her work integrates advanced immunological diagnostics, molecular biology, and national livestock immunization programs that directly contribute to animal health surveillance and disease control. Her academic training culminated in a doctoral degree in cancer immunology from Cairo University, where her research focused on circulating cancer stem cells and photothermal nanotherapy as predictive and monitoring tools for tumor response. She has conducted advanced international research training at University of California San Francisco, gaining high-level proficiency in flow cytometry, immunofluorescence, and human stem cell analysis, and later expanded her translational oncology experience as a visiting research fellow at the Cancer Institute of Montpellier, working on nanoparticle-mediated RNA delivery to tumor-infiltrating immune cells. Her scientific output includes multiple peer-reviewed publications in high-impact journals and international conference proceedings, with her work receiving sustained scholarly citations and global academic recognition. Her research collaborations span institutions in North America, Europe, and the Middle East, reflecting her active role in international scientific networks in stem cell biology, cancer immunology, and nanomedicine. Beyond laboratory research, she contributes to national capacity building through scientific training, quality assurance in diagnostic immunology, and public health–oriented animal disease control programs. Her work has direct societal impact through improvements in cancer diagnostics, advancement of immunotherapeutic strategies, and strengthening of zoonotic disease surveillance, positioning her as a globally engaged scientist at the intersection of experimental research, translational medicine, and public health. She has 2 citations from 2 documents with an h-index of 1.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Xiao, T., Eze, U. C., Charruyer-Reinwald, A., Weisenberger, T., Khalifa, A., … (2024). Short cell cycle duration is a phenotype of human epidermal stem cells. Stem Cell Research & Therapy, 15(1), 76.

2. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Ragab, E., … (2021). Quantitative flow cytometry assessment of feline circulatory breast cancer stem cells. Advances in Animal and Veterinary Sciences, 9(12), 2201–2215.

3. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H. H., Ragab, E., … (2025). Gold nano-rod (AuNR)-mediated plasmonic photothermal therapy in feline mammary carcinoma: Assessing metastatic and nonmetastatic outcomes. Veterinary Oncology, 2(1), 33.

4. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H., Ragab, E., … (2022). Prevention of in situ recurrence and distant metastasis in feline mammary carcinoma treated with plasmonic photothermal therapy.

 

Huiling Chen | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Huiling Chen | Oncology | Best Researcher Award 

Physician | Lanzhou University | China

Dr. Huiling Chen is a distinguished physician and researcher at The Second Hospital and Clinical Medical School, Lanzhou University, recognized for her significant contributions to the field of hematologic malignancies, particularly acute myeloid leukemia (AML). Her research primarily focuses on advancing evidence-based therapeutic strategies through systematic reviews and meta-analyses that inform clinical decision-making and improve patient outcomes. As the lead investigator and corresponding author of a comprehensive meta-analysis published in the Annals of Hematology, Dr. Chen evaluated the efficacy and safety of venetoclax plus azacitidine regimens in relapsed or refractory AML, providing vital insights into their clinical utility and identifying combination chemotherapy as a promising approach for improving remission outcomes. Her expertise lies in clinical epidemiology, biostatistics, and the design and interpretation of complex data in oncology research. Through collaborations with multidisciplinary teams across national and international institutions, she has contributed to multicenter studies that bridge gaps between clinical research and real-world applications. Her scholarly work exemplifies a commitment to scientific rigor, innovation, and translational relevance, with her findings influencing the direction of future clinical trials and treatment paradigms for high-risk AML populations. Dr. Chen’s research efforts aim to optimize therapeutic interventions, enhance personalized treatment planning, and advance precision medicine in hematology. Beyond her academic accomplishments, she upholds a strong dedication to mentoring and fostering collaborative research environments that encourage cross-institutional partnerships and scientific dialogue. Her contributions embody the integration of analytical excellence, clinical insight, and humanitarian vision, underscoring her role as a leader shaping the future of hematologic cancer research and its impact on global health.

Profile: ORCID 

Featured Publications

1. Chen, H., Li, X., Gao, L., Zhang, D., & Han, T. (2022, August). Construction and identification of an immortalized rat intestinal smooth muscle cell line. Neurogastroenterology & Motility.

2. Chen, H., Ren, X., Xu, S., Zhang, D., & Han, T. (2022, July). Optimization of lipid nanoformulations for effective mRNA delivery. International Journal of Nanomedicine.

3. Chen, H., Han, T., Gao, L., & Zhang, D. (2022, January). The involvement of glial cell-derived neurotrophic factor in inflammatory bowel disease. Journal of Interferon & Cytokine Research.

4. Chen, H., Zeng, P., & Zhang, D. (2020, February). Haemophagocytic syndrome triggered by acute lymphoblastic leukaemia with t(9;22)(p24; q11.2). Journal of International Medical Research.

Meng Li | Clinical Medicine | Best Medical Scientist Award

Published on by Health Scientists

Mr. Meng Li | Clinical Medicine | Best Medical Scientist Award 

professor | Dandong Central Hospital | China

Dr. Meng Li currently serves as a Teaching Secretary and Professor of General Surgery at China Medical University and is also affiliated with Dandong Central Hospital, the largest Grade-A general hospital in the Liaodong region. She earned her Ph.D. in Oncology from China Medical University, one of the leading medical universities in China. Her primary research focuses on digestive tract tumor surgery, hepatobiliary and pancreatic surgery, gastrointestinal oncology, and the comprehensive treatment of malignant tumors. Over the years, Dr. Li has contributed significantly to the medical research community, publishing seven SCI/Scopus-indexed papers, including works on predictive models for intraabdominal infections after radical gastrectomy, gene signatures in hepatocarcinoma prognosis, and gut microbiota’s role in urological cancers. Her research has accumulated over 47 citations and has advanced understanding in cancer surgery and molecular oncology. In recognition of her outstanding contributions, she received the First Prize of the Liaoning Province Science and Technology Progress Award in 2023. Dr. Li actively participates in collaborative projects, including two National Natural Science Foundation programs, and holds memberships in several professional bodies such as the Chinese Anti-Cancer Association and the Chinese Pancreatic Disease Society. She also serves as an Editorial Board Member of the Cancer Research Journal (CRJ), a guest editor for two scientific journals, and a review editor for others, reflecting her strong commitment to scientific advancement and peer review excellence. Her long-term goal is to deepen molecular insights into cancer and improve clinical outcomes through innovative surgical research. He has 213 citations from 17 documents with an h-index of 7.

Profiles: Scopus | ORCID

Featured Publications

1. Feng, Y., Yang, J., Li, M., Tang, L., Sun, S., & Wang, Y. (2024). A Bayesian network for simultaneous keyframe and landmark detection in ultrasonic cine.

2. Li, Z.-W., Wu, J.-T., Bi, Y., Li, M.-M., Naseem, A., Pan, J., Guan, W., Hao, Z.-C., Kuang, H.-X., & Chen, Q.-S. (2024). A new triterpenoid saponin and a new natural saponin from the roots of Bupleurum scorzonerifolium Willd.

3. Yu, X., Feng, B., Wu, J., & Li, M. (2024). A novel anoikis-related gene signature can predict the prognosis of hepatocarcinoma patients.

4. Yu, X., Tang, W., Bai, C., Li, R., Feng, B., Wu, J., Guo, X., Chen, H., & Li, M. (2024). A predictive model for intraabdominal infection after radical gastrectomy in elderly patients.

5. Li, M., Zhang, X., Chen, K., Miao, Y., Xu, Y., Sun, Y., Jiang, M., Liu, M., Gao, Y., & Xue, X. (2024). Alcohol exposure and disease associations: A Mendelian randomization and meta-analysis on weekly consumption and problematic drinking.

Dana Chase | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Dana Chase | Oncology | Best Researcher Award

Professor at University of California| United States

Dr. Dana M. Chase is a distinguished gynecologic oncologist whose career integrates clinical excellence, academic leadership, and impactful research. As an associate professor and fellowship program director, she has significantly advanced women’s cancer care through innovative research, particularly in ovarian, cervical, and uterine malignancies, with her findings widely published in leading journals and presented at major international conferences. Her academic training and subspecialty expertise provide a strong foundation for her role in bridging clinical practice with evidence-based research, while her leadership in mentoring fellows and trainees highlights her dedication to education. Dr. Chase has also been recognized with numerous awards for patient care, teaching, and research, underscoring her influence across multiple domains. Beyond academia, she contributes actively to community engagement and patient advocacy, further broadening the reach of her work. With a clear commitment to advancing gynecologic oncology and inspiring future researchers, she stands out as an exemplary candidate for recognition.

Professional Profile

Scopus Profile | ORCID Profile

 

Education

Dr. Dana M. Chase has pursued a comprehensive and rigorous educational path that laid the foundation for her distinguished career in gynecologic oncology. She began her academic journey with an undergraduate degree in Latin American Studies, followed by postbaccalaureate premedical studies that strengthened her scientific background. She then earned her medical degree, which was followed by a residency in obstetrics and gynecology, where she gained extensive clinical training and developed a strong interest in women’s health and oncology. Building upon this, she completed a highly specialized fellowship in gynecologic oncology, where she refined her expertise in managing complex gynecologic cancers and gained advanced skills in both research and clinical practice. This blend of humanities, medical training, and subspecialty fellowship has enabled her to combine a compassionate, patient-centered approach with scientific rigor. Her educational background not only shaped her clinical and research capabilities but also prepared her for leadership in academic medicine.

Experience

Dr. Dana M. Chase has built an impressive professional career that spans academic medicine, clinical practice, and research leadership in gynecologic oncology. She has served in key academic roles, including assistant, associate, and full professorships at leading medical institutions, where she has combined teaching, mentorship, and program development with advancing cancer care. As a fellowship program director, she has guided the training of future specialists, emphasizing innovation, evidence-based practice, and patient-centered care. Clinically, she has held positions as a gynecologic oncologist across major hospitals and cancer centers, where she provided advanced surgical and medical management for women with complex cancers. Her leadership extends beyond the clinic into research, with active participation in national and international collaborations, presentations at major conferences, and contributions to peer-reviewed publications. Recognized for her excellence in teaching, patient care, and research, Dr. Chase’s professional journey highlights her as a dedicated physician, educator, and influential researcher.

Research Interest

Dr. Dana M. Chase’s research interests center on advancing the understanding and treatment of gynecologic cancers, with a strong focus on ovarian, cervical, and uterine malignancies. She is particularly committed to exploring novel therapeutic approaches, including the integration of targeted therapies and innovative clinical trial designs that aim to improve patient survival and quality of life. Her work also extends to studying the role of the vaginal microbiome, inflammation, and genetic factors in cancer development and progression, highlighting her interest in precision medicine and translational research. Dr. Chase has been actively involved in collaborative projects that bridge laboratory science with clinical applications, ensuring that discoveries translate into tangible benefits for patients. Additionally, she is passionate about survivorship research, patient advocacy, and educational outreach, which complement her scientific contributions by addressing the holistic needs of women with cancer. Her research embodies a vision of innovation, collaboration, and improved patient outcomes.

Award and Honor

Dr. Dana M. Chase has received numerous awards and honors that reflect her excellence in research, teaching, clinical care, and leadership in gynecologic oncology. Early in her career, she was recognized with prestigious research and presentation awards from leading professional organizations, acknowledging her contributions to advancing the understanding and management of gynecologic cancers. She has earned accolades such as merit and travel awards from oncology foundations, humanitarian and teacher of the year honors, and recognition for outstanding research papers and clinical presentations. Her commitment to patient care has also been highlighted through physician recognition awards and consistent listings among top doctors in major medical publications. These distinctions not only demonstrate her academic and clinical achievements but also underscore her influence as a mentor, educator, and advocate. Collectively, her awards and honors signify a career dedicated to innovation, excellence, and service, establishing her as a respected leader in women’s health and oncology.

Research Skill

Dr. Dana M. Chase possesses a wide range of research skills that reflect her expertise in gynecologic oncology and her commitment to advancing scientific knowledge in women’s cancer care. She is highly skilled in designing and conducting clinical trials, particularly those exploring new therapeutic strategies, targeted treatments, and survivorship outcomes. Her ability to integrate translational research with clinical applications demonstrates proficiency in bridging laboratory findings with patient-centered interventions. She has extensive experience in data analysis, interpretation of complex clinical outcomes, and dissemination of results through peer-reviewed publications and international conference presentations. Additionally, she is adept at developing collaborative research initiatives, both nationally and internationally, fostering multidisciplinary partnerships that enhance the scope and impact of her work. Her research skills extend beyond technical expertise to include mentorship, as she effectively guides trainees and junior researchers in developing their scholarly work. Collectively, these strengths underscore her role as a capable and innovative researcher.

Publications Top Notes

Title: Navigating complexities of polymorphic microbiomes in endometrial cancer
Authors: Dana M. Chase, et al.

Title: Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US
Authors: Dana M. Chase, et al.

Title: Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel
Authors: Dana M. Chase, et al.

Title: Treatment patterns and outcomes by mismatch repair/microsatellite instability status among patients with primary advanced or recurrent endometrial cancer in the United States
Authors: Dana M. Chase, et al.

Title: Clinical Trial Screening in Gynecologic Oncology: Defining the Need and Identifying Best Practices
Authors: Dana M. Chase, et al.

Conclusion

In conclusion, Dr. Chase is a highly deserving candidate for the Best Researcher Award, as her contributions demonstrate excellence in clinical care, education, and translational research. Her leadership in advancing gynecologic oncology, dedication to training the next generation of specialists, and consistent engagement in impactful research reflect a career committed to improving both science and society. With her proven track record of innovation and service, combined with the potential to expand into new frontiers of cancer research, she stands as a strong role model and an exemplary figure in the academic and medical community.

Francis Worden | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Francis Worden | Oncology | Best Researcher Award

Clinical Professor at University of Michigan, United States

Francis Worden is a highly respected clinical professor of internal medicine with a specialization in hematology and oncology at the University of Michigan. His career reflects a steady progression through academic and leadership roles, demonstrating both dedication to patient care and commitment to advancing cancer research. He has focused his research on organ preservation strategies in head and neck cancers, as well as developing medical treatment approaches for advanced thyroid and adrenal cancers. His extensive publication record in peer-reviewed journals highlights his contributions to improving outcomes in oncology, and his collaborative work with multidisciplinary teams has advanced both clinical practice and scientific understanding. In addition to research, he has played an important role in medical education and mentorship, particularly through directing fellowship programs and guiding future oncologists. With a balance of clinical excellence, research productivity, and educational leadership, he is recognized as an influential figure in academic oncology.

Professional Profile

 Scopus Profile | ORCID Profile 

Education

Francis Worden’s educational background reflects a strong and diverse foundation in both the pharmaceutical sciences and medicine. He first completed a bachelor’s degree in pharmacy at Purdue University, which provided him with a deep understanding of pharmacology and drug therapy principles. Building on this knowledge, he pursued a medical degree at Indiana University School of Medicine, where he was part of the Pediatric Honors Program, demonstrating early distinction in his training. Following medical school, he undertook an internship and residency in internal medicine and pediatrics at Detroit Medical Center-Wayne State University, which gave him dual expertise and broadened his clinical skills. He then completed a fellowship in hematology and medical oncology at the University of Michigan Health System, which set the stage for his lifelong career in oncology. This educational journey, spanning pharmacy, medicine, and advanced subspecialty training, has shaped his ability to integrate research, clinical care, and education in cancer medicine.

Experience

Francis Worden has built an extensive professional career that integrates clinical practice, academic leadership, and research in oncology. He began his work as a pharmacist before fully transitioning into medicine, where he gained experience as a physician in urgent care, emergency settings, and hospice care, reflecting a broad understanding of patient needs across different stages of illness. At the University of Michigan, he advanced through multiple academic roles, ultimately becoming a clinical professor in hematology and oncology. His leadership positions have included serving as a medical oncology clinic team leader, medical director for hospice programs, and director of the hematology/oncology fellowship program, where he played a pivotal role in mentoring and training future oncologists. Alongside his clinical responsibilities, he has maintained an active research portfolio, contributing to advancements in head and neck cancer management, thyroid and adrenal cancers, and strategies for organ preservation. His career embodies dedication to patient care, education, and impactful research.

Research Interest

Francis Worden’s research interests are centered on advancing treatment strategies for complex cancers with a strong emphasis on improving patient outcomes and quality of life. A major focus of his work has been organ preservation in head and neck oncology, where he has contributed to developing approaches that aim to maintain function without compromising survival. He is deeply involved in exploring systemic therapies for advanced and metastatic head and neck cancers, seeking to refine chemoradiation protocols and identify biomarkers that predict response to therapy. His research also extends to the management of rare but challenging malignancies such as adrenal and metastatic thyroid cancers, where he has investigated therapeutic options that may improve survival in patients with limited treatment choices. Additionally, he maintains an interest in medical education research, particularly in shaping oncology training programs. His efforts reflect a balance of translational and clinical research that bridges innovation with patient-centered care.

Award and Honor

Throughout his career, Francis Worden has earned recognition for his significant contributions to oncology, education, and patient care. His dedication to advancing cancer treatment through clinical research has positioned him as a respected figure in the medical community, earning honors that reflect both his scientific impact and his commitment to improving outcomes for patients with complex cancers. As a leader in head and neck oncology, he has been acknowledged for his role in pioneering organ preservation strategies and contributing to the development of evidence-based therapies. His long-standing service as a mentor and fellowship program director has also brought him distinction within academic medicine, highlighting his influence on training the next generation of oncologists. While much of his recognition is embedded in professional appointments, leadership roles, and invitations to collaborate on national clinical guidelines, these achievements collectively illustrate the esteem with which his peers and institutions regard his professional accomplishments.

Research Skill

Francis Worden possesses a wide range of research skills that have enabled him to make meaningful contributions to oncology and medical education. He demonstrates strong expertise in designing and conducting clinical trials, particularly in developing and evaluating treatment strategies for head and neck, thyroid, and adrenal cancers. His ability to integrate clinical practice with research allows him to identify relevant patient-centered questions and translate them into impactful studies. He is skilled in collaborative, multidisciplinary research, working with experts in radiation oncology, surgery, pathology, and radiology to generate comprehensive approaches to cancer management. His proficiency in analyzing clinical outcomes, interpreting imaging, and exploring biomarker-driven therapies reflects a capacity to connect clinical data with translational science. Additionally, his scholarship and publication record highlight his ability to effectively disseminate findings in peer-reviewed journals, influencing both practice and future research. These skills underscore his strength as a clinician-researcher dedicated to advancing cancer care.

Publications Top Notes

Title: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: Jena D. French  Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles,

Title: Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: Jena D. French Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis

Title: Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: Jena D. French  Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis, Bhavana Konda, Ramona Dadu

Title: Supplementary Data S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: Jena D. French  Bryan R. Haugen

Title: Supplementary Data S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: Jena D. French Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis, Bhavana Konda, Ramona Dadu, Eric J. Sherman, Shaylene McCue, Nathan R. Foster, et al.

Conclusion

Dr. Francis Worden is a highly accomplished academic oncologist whose career reflects deep commitment to clinical care, education, and impactful cancer research. His contributions to head and neck cancer management and organ preservation strategies are particularly noteworthy and have advanced patient care significantly. While areas such as expanding independent authorship visibility, diversifying into emerging oncology frontiers, and showcasing international leadership could further enhance his candidacy, his overall profile demonstrates excellence, longevity, and leadership in oncology research. He is a strong candidate for a Best Researcher Award, particularly in fields related to clinical oncology, translational research, and academic mentorship.